Global Health Outcomes Research, Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK.
J Affect Disord. 2013 Jul;149(1-3):182-8. doi: 10.1016/j.jad.2013.01.020. Epub 2013 Mar 19.
To investigate the impact of somatic symptoms on the severity and course of depression in Asian patients treated for an acute episode of major depressive disorder (MDD).
Three-month prospective observational study of 917 patients with MDD in psychiatric care settings of which 909 had complete main baseline data. Depression severity was assessed using the physician-rated Clinical Global Impression of Severity (CGI-S) and 17-item Hamilton Depression Rating Scale (HAMD17), and somatic symptoms were assessed using the patient-rated 28-item Somatic Symptom Inventory (SSI). Cluster analysis using baseline SSI scores grouped patients into 3 clusters with no/few, moderate or severe somatic symptoms. Four factors of SSI (pain, autonomic symptoms, energy, and central nervous system) were defined and regression analyses identified which factors were associated with remission and response at 3 months follow-up.
Baseline depression severity (HAMD17 and CGI-S scores) was associated with more severe somatic symptoms. Remission rates differed between clusters of patients: 68.4%, 54.7% and 29.3% for no/few, moderate and severe somatic symptoms, respectively (p<0.0001). Corresponding response rates were 81.8%, 72.1% and 55.2% (p<0.0001). Pain symptoms were the somatic symptoms most associated with these clinical outcomes at 3 months.
Only patients diagnosed with MDD in psychiatric care were assessed.
Somatic symptoms are frequent among Asian patients in psychiatric care for MDD and are associated with greater clinical severity and lower response and remission rates. Among somatic symptoms, pain symptoms have the greatest prognostic value and should be taken into account when treating patients with depression.
调查躯体症状对亚洲患者接受治疗的急性重性抑郁障碍(MDD)发作严重程度和病程的影响。
对 917 例在精神科医疗机构接受治疗的 MDD 患者进行为期 3 个月的前瞻性观察性研究,其中 909 例患者具有完整的主要基线数据。使用医生评定的临床总体印象严重程度量表(CGI-S)和 17 项汉密尔顿抑郁量表(HAMD17)评估抑郁严重程度,使用患者自评的 28 项躯体症状清单(SSI)评估躯体症状。使用基线 SSI 评分进行聚类分析,将患者分为无/少躯体症状、中度或重度躯体症状 3 个亚组。定义 SSI 的 4 个因子(疼痛、自主症状、精力和中枢神经系统),并进行回归分析,以确定哪些因子与 3 个月随访时的缓解和应答相关。
基线抑郁严重程度(HAMD17 和 CGI-S 评分)与更严重的躯体症状相关。不同亚组患者的缓解率存在差异:无/少躯体症状、中度和重度躯体症状患者的缓解率分别为 68.4%、54.7%和 29.3%(p<0.0001)。相应的应答率分别为 81.8%、72.1%和 55.2%(p<0.0001)。疼痛症状是 3 个月时与这些临床结局最相关的躯体症状。
仅评估了在精神科医疗机构接受治疗的 MDD 患者。
躯体症状在亚洲精神科医疗机构接受 MDD 治疗的患者中较为常见,与更大的临床严重程度以及更低的应答和缓解率相关。在躯体症状中,疼痛症状具有最大的预后价值,在治疗抑郁症患者时应予以考虑。